Gilead Sciences rides Sovaldi launch for strong first quarter; Amgen falls short
By Jennifer Boggs
Thursday, April 24, 2014
The eagerly awaited earnings season kicked off this week, but investors hoping for first-quarter sales data to restore stability to the selloff-plagued biotech sector are unlikely to see a quick fix as the drug pricing debate continues to garner headlines. But promising pipeline opportunities should keep the top four big biotechs on steady ground in the year ahead.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.